Acasti Pharma (ACST) Stock Price, News & Analysis

Company Overview

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Key Stats

• Today's Range: C$0.56 to C$0.58
• 50-Day Range: C$0.58 to C$0.58
• 52-Week Range: C$0.47 to C$1.66
• Volume: 2,450 shs
• Average Volume: 6,576 shs
• Market Capitalization: C$18.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACST Stock Analysis - Frequently Asked Questions

How have ACST shares performed this year?

Acasti Pharma's stock was trading at C$0.58 at the beginning of 2025. Since then, ACST shares have increased by 0.0% and is now trading at C$0.58.
View the best growth stocks for 2025 here.

How do I buy shares of Acasti Pharma?

Shares of ACST stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include Genius Brands International (GNUS), Tesla (TSLA), Workhorse Group (WKHS), Nikola (NKLA), SCYNEXIS (SCYX) and

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: CVE:ACST
• Previous Symbol: CVE:APO
• CIK: N/A
• Web: www.acastipharma.com
• Phone: +1-450-6864555
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-10,537,760.56
• Net Margins: -388.46%
• Pretax Margin: N/A
• Return on Equity: -35.76%
• Return on Assets: -8.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.44
• Quick Ratio: 9.41

Sales & Book Value

• Annual Sales: C$2.71 million
• Price / Sales: 6.71
• Cash Flow: C$0.93 per share
• Price / Cash Flow: 0.63
• Book Value: C$0.86 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 31,369,490
• Free Float: N/A
• Market Cap: C$18.19 million
• Optionable: Not Optionable
• Beta: 1.22